Cargando…

Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy

Malignant glioma, or glioblastoma, is the most common and lethal form of brain tumor with a median survival time of 15 months. The established therapeutic regimen includes a tripartite therapy of surgical resection followed by radiation and temozolomide (TMZ) chemotherapy, concurrently with radiatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sengupta, Sadhak, Marrinan, Jaclyn, Frishman, Caroline, Sampath, Prakash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486128/ https://www.ncbi.nlm.nih.gov/pubmed/23133490 http://dx.doi.org/10.1155/2012/831090

Ejemplares similares

Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
por: Yang, Seung-Ho, et al.
Publicado: (2006)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy
por: Sengupta, Sadhak, et al.
Publicado: (2014)

The strategy for enhancing temozolomide against malignant glioma
por: Nakada, Mitsutoshi, et al.
Publicado: (2012)

Mesenchymal Stem Cells Modified with a Single-Chain Antibody against EGFRvIII Successfully Inhibit the Growth of Human Xenograft Malignant Glioma
por: Balyasnikova, Irina V., et al.
Publicado: (2010)

Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas
por: Li, Ming-Yang, et al.
Publicado: (2016)

Treating malignant glioma in Chinese patients: update on temozolomide
por: Chang, Liang, et al.
Publicado: (2014)

COT-06 HBV REACTIVATION DURING AND AFTER THE TREATMENT OF MALIGNANT GLIOMA WITH TEMOZOLOMIDE
por: Kanamori, Masayuki, et al.
Publicado: (2019)

Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma
por: Wei, Shoufeng, et al.
Publicado: (2022)

Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo
por: Ulasov, I V, et al.
Publicado: (2009)

Clinical efficacy of early postoperative intensity-modulated radiotherapy combined with Temozolomide chemotherapy in the treatment of patients with malignant glioma
por: Zhou, Hongyang, et al.
Publicado: (2022)

Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide
por: Kanzawa, T, et al.
Publicado: (2003)

Antitumor effect of fibrin glue containing temozolomide against malignant glioma
por: Anai, Shigeo, et al.
Publicado: (2014)

Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea
por: Bae, So Hyun, et al.
Publicado: (2014)

Cytomegalovirus Hemorrhagic Cystitis in a Malignant Glioma Patient Treated with Temozolomide
por: Furukawa, Ryutaro, et al.
Publicado: (2018)

Retracted: Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma
por: Engineering, Journal of Healthcare
Publicado: (2023)

Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group
por: AOKI, Tomokazu, et al.
Publicado: (2017)

Recurrence of herpes simplex encephalitis associated with temozolomide chemoradiation for malignant glioma: a case report and review of the literature
por: Christman, Mitalee P., et al.
Publicado: (2014)

The Presence of IL-17A and T Helper 17 Cells in Experimental Mouse Brain Tumors and Human Glioma
por: Wainwright, Derek A., et al.
Publicado: (2010)

A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma
por: Dinnes, J, et al.
Publicado: (2002)

KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment
por: D'Alessandro, Giuseppina, et al.
Publicado: (2016)

Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
por: Wong, Eric T., et al.
Publicado: (2016)

Radiation and chemotherapy for high‐risk lower grade gliomas: Choosing between temozolomide and PCV
por: McDuff, Susan G. R., et al.
Publicado: (2019)

Survival Time after Surgical Debulking and Temozolomide Adjuvant Chemotherapy in Canine Intracranial Gliomas
por: Hidalgo Crespo, Emma, et al.
Publicado: (2022)

Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas
por: Tu, Zewei, et al.
Publicado: (2022)

A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients
por: Li, Yurong, et al.
Publicado: (2023)

β-arrestin 1 Overexpression Increases Temozolomide Resistance in Human Malignant Glioma Cells
por: ARTENE, S.A., et al.
Publicado: (2017)

Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest
por: Wang, Peng, et al.
Publicado: (2016)

MicroRNA-93 promotes the malignant phenotypes of human glioma cells and induces their chemoresistance to temozolomide
por: Chen, Rui, et al.
Publicado: (2016)

Response of Leptomeningeal Dissemination of Anaplastic Glioma to Temozolomide: Experience of Two Cases
por: Bae, Jin Woo, et al.
Publicado: (2017)

Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide
por: Weyhenmeyer, Birgit C., et al.
Publicado: (2016)

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
por: Ohba, Shigeo, et al.
Publicado: (2021)

Targeting autophagy to sensitive glioma to temozolomide treatment
por: Yan, Yuanliang, et al.
Publicado: (2016)

Glioma and temozolomide induced alterations in gut microbiome
por: Patrizz, Anthony, et al.
Publicado: (2020)

Temozolomide Chronotherapy in Glioma: A Systematic Review
por: Jia, Jason L., et al.
Publicado: (2023)

A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma
por: Cai, Yonghua, et al.
Publicado: (2022)

Liver toxicity during temozolomide chemotherapy caused by Chinese herbs
por: Melchardt, Thomas, et al.
Publicado: (2014)

Piperine synergistically enhances the effect of temozolomide against temozolomide-resistant human glioma cell lines
por: Jeong, Somi, et al.
Publicado: (2020)

Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy
por: Ming, Jianguang, et al.
Publicado: (2017)

Cinnamophilin enhances temozolomide-induced cytotoxicity against malignant glioma: the roles of ROS and cell cycle arrest
por: Tai, Shih-Hang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n92ccg7e5b0d8qcpsapcbk2afs